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Abstract. Introduction: The MPAL comprise 2
classification  has  separated  two  groups  in  MPAL  based  on  t(9;22)  positivity  and  MLL 
rearrangement. Aims & Objectives:
BCR-ABL transcript in MPAL cases using  the RT
hematological remission post induction. 
on Flow-cytometry based on the current WHO 2008 criteria were enrolled. In all the cases Bone 
marrow or peripheral blood sample in EDTA was processed for molecular studies and the RT
reaction  carried  out  using  primers  specific  to  the  t  (9;22)  and  t(4;11)  tra
induction check marrow slides were also reviewed. 
(70%) were adult and 3/10 (30%) pediatric cases. A total of 4/10 (40%) cases showed positivity for 
the t(9;22) transcript and none for t (4
1/10(10%) pediatric case. The BCR
(66%)  and  e1a2  (p190)  in  1/3  (33.3%)  case.  The  single  pediatric  case  was  positive  for  b3a2 
transcript. Discussion & Conclusion:
low  platelet  count  (p<0.05).  The  positive  cases  also  showed  hematological  remission  at  post 
induction check marrow (blasts<5%). This could partly be explained due to good r
imatinib added to the treatment protocol.
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The MPAL comprise 2-5% of all acute leukemia. The present WHO 2008 
classification  has  separated  two  groups  in  MPAL  based  on  t(9;22)  positivity  and  MLL 
Aims & Objectives: The aim of the present pilot study is to note the frequency of 
ABL transcript in MPAL cases using  the RT-PCR assay and to correlate the status  with 
hematological remission post induction. Materials & Methods: A total of 10 MPAL cases classified 
cytometry based on the current WHO 2008 criteria were enrolled. In all the cases Bone 
marrow or peripheral blood sample in EDTA was processed for molecular studies and the RT
reaction  carried  out  using  primers  specific  to  the  t  (9;22)  and  t(4;11)  tra
induction check marrow slides were also reviewed. Results: Out of the total 10 MPAL cases, 7/10 
(70%) were adult and 3/10 (30%) pediatric cases. A total of 4/10 (40%) cases showed positivity for 
the t(9;22) transcript and none for t (4;11). Of the 4 positive cases, 3/10(30%) were adult cases and 
1/10(10%) pediatric case. The BCR-ABL transcript type in adult cases was b3a2 (p210) in  2/3 
(66%)  and  e1a2  (p190)  in  1/3  (33.3%)  case.  The  single  pediatric  case  was  positive  for  b3a2 
Discussion & Conclusion: All the 4 positive MPAL cases presented with high TLC and 
low  platelet  count  (p<0.05).  The  positive  cases  also  showed  hematological  remission  at  post 
induction check marrow (blasts<5%). This could partly be explained due to good r
imatinib added to the treatment protocol.
Acute leukemia with a mixed phenotype 
5%  of  all  acute 
leukemias.  Immunophenotyping  for  B/T/Myeloid 
markers is necessary for detection of Mixed Phenotype 
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5% of all acute leukemia. The present WHO 2008 
classification  has  separated  two  groups  in  MPAL  based  on  t(9;22)  positivity  and  MLL 
The aim of the present pilot study is to note the frequency of 
PCR assay and to correlate the status  with 
A total of 10 MPAL cases classified 
cytometry based on the current WHO 2008 criteria were enrolled. In all the cases Bone 
marrow or peripheral blood sample in EDTA was processed for molecular studies and the RT-PCR 
reaction  carried  out  using  primers  specific  to  the  t  (9;22)  and  t(4;11)  translocation.  The  post 
Out of the total 10 MPAL cases, 7/10 
(70%) were adult and 3/10 (30%) pediatric cases. A total of 4/10 (40%) cases showed positivity for 
;11). Of the 4 positive cases, 3/10(30%) were adult cases and 
ABL transcript type in adult cases was b3a2 (p210) in  2/3 
(66%)  and  e1a2  (p190)  in  1/3  (33.3%)  case.  The  single  pediatric  case  was  positive  for  b3a2 
All the 4 positive MPAL cases presented with high TLC and 
low  platelet  count  (p<0.05).  The  positive  cases  also  showed  hematological  remission  at  post 
induction check marrow (blasts<5%). This could partly be explained due to good response to the 
.  Immunophenotyping  for  B/T/Myeloid 
markers is necessary for detection of Mixed Phenotype Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
acute  leukemias.  The  WHO  2008  classification 
identifies  two  subtypes  of  MPAL  with  characteristic 
genetic  lesion  as  separate  entities:- i)  MPAL  with  t 
(9;22) and ii) MPAL with MLL rearrangements. The 
incidence  of  MPAL  with  t(9;22)  and  MLL 
rearrangement  in  adults  is 28-30% and  2-3%  and  in 
children 3-5% and 10-15% respectively
1. The aim of 
the present study was to note the frequency of BCR-
ABL  positivity  in  MPAL  cases  using  the  Reverse 
Transcriptase  Polymerase  Reaction  Assay  (RT-PCR) 
and  to  correlate  BCR-ABL  positivity  with  status  of 
hematological remission at 1
st check marrow.
Materials and Methods. The study was a prospective 
study carried out over a period of one year from July 
2010-June  2011.  Inclusion  criteria  included:  (i)  All 
cases  of  Acute  leukemia  coming  for  Bone  marrow 
examination to Department of Hematology, PGIMER, 
Chandigarh and diagnosed as Mixed Phenotype Acute 
Leukemia  according  to  WHO 2008  criteria  on  Bone
marrow examination and Immunophenotyping. (ii) All 
MPAL Cases receiving treatment in the Institute and 
having complete follow-up details of 1
st check marrow. 
Cases  of  Acute leukemia  with  aberrant  B/T/Myeloid 
marker  expression  on  immunophenotyping,  known 
cases  of  Chronic  Myeloid  leukemia  (CML)  in  Blast 
crisis and cases with incomplete follow-up details/not 
receiving treatment in the institute were excluded from 
the study.
Methodology. RNA was extracted from 1-2ml Bone 
Marrow aspirate in EDTA or 3-5ml Peripheral blood 
(if  blasts  >  20%  and  TLC>  50X10
9  /L)  using  the 
commercial  kit  (Qiagen  Miniamp  RNA  Blood  kit) 
according  to  manufacturer’s  instructions.  The  RNA 
quality  was  checked  in  each  case  by  absorbance  at 
260nm in a spectrophotometer and by running a 1% 
formaldehyde gel for  18s and  28s RNA bands. This 
was  followed  by  cDNA  synthesis  according  to  the 
commercial  kit  protocol  (Fermantas  cDNA  kit).  The 
quality  of  cDNA  was  checked  using  primers  for  β-
Actin  housekeeping  gene.    Reverse  Transcriptase 
polymerase  chain  reaction  was  carried  out  using 
primers  specific  for  p210  (b3a2  and  b2a2)
2 adapted 
from  the  study  of  Jones  et  al  and  the  protocol  was 
standardized in our laboratory in 2004 for detection of 
p210  transcript  in  CML  cases.  A  separate  Multiplex 
RT-PCR  was  done  for  detection  of  p190  and  MLL-
AF4 transcript as adapted from study by Pakakasama et 
al
3. This Multiplex RT-PCR is routinely used in our 
laboratory as a screening PCR for detection of common 
chimeric  fusion  transcripts  in  ALL  cases.  The  PCR 
conditions for both the PCR are outlined below and the 
primer  sequences  and  the  product  base  size  are 
highlighted  in  the  table  1.  The  BCR-ABL  PCR  for 
p210  transcripts (b3a2  and  b2a2)  was  carried  out  in 
following  conditions:  Pre-Denaturation- 94c-4  mts  –
one cycle; Denaturation-94c-1 mt, Annealing-63c-2 mt 
and  Extension- 72c- 3  mt  for  32  cycles.  This  was 
followed by one cycle of final Extension at 72c-10 mt.  
The Multiplex RT-PCR for p190 (e1a2) transcript and 
the  MLL-AF4  transcript  was  carried  out  as  follows: 
The PCR was carried out in a final volume of 25 ul 
with 1 ul cDNA, 1x PCR buffer, 200 uM dNTP, 1.5 
mM MgCl2, 120 nM of each primer pair and 1 unit of 
Tag polymerase. After initial denaturation step at 94
0 C 
for 3 min, the 35 cycles of PCR condition including 94
0
C for 45 s, 63
0 C for 1 min, and 72
0 C for 1.5 min were 
performed. The final extension for 7 min at 72
0 C was 
set to ensure a complete extension of all PCR products. 
The PCR products were then run on agarose gel and 
stained with Ethidium Bromide and visualized under 
UV-Gel doc for  b3a2 (385bp), b2a2 ( 310bp) and e1a2 
(521bp)  bands.  Appropriate  positive  and  negative 
controls were included in each run.
Review  of  Geimsa  stained  Bone  marrow  and 
peripheral blood slides at 1
st check marrow (Day 14-
Pediatric cases & Day 28-Adult cases) for Remission 
status (Standard Remission criteria- Hb>10g/dl; TLC 
4-12X 10
9/L; Platelet 150-450 x 10
9/L; Bone marrow 
blasts<5%;  No  Auer  Rod;  No  blasts  in  peripheral 
blood)  was  performed  and  relevant  data  analyzed. 
Cytogenetic samples were taken in all cases.
Ethical  Justification. The blood  sample  used in  the 
study  is  withdrawn  as  a  part  of  routine  diagnostic 
work-up of the patient and no additional sample pricks 
were  performed.  Prior  informed  consent  was  taken 
from all patients/guardians before withdrawl of sample.
Table 1. Primer sequences and band sizes for BCR-ABL and MLL-AF4 transcript
S. No. Transcript Primer sequence Product size 
(bp)
1. b3a2 (p210) BCR-b2 5’-ACAGAATTCCGCTGACCATCAATAAG-3’
ABL-a2 5’-TGTTGACTGGCGTGATGTAGTTGCTTGG-3’ 385
2. b2a2 (p210) BCR-b2 5’-ACAGAATTCCGCTGACCATCAATAAG-3’
ABL-a2 5’-TGTTGACTGGCGTGATGTAGTTGCTTGG-3’ 310
3. e1a2 (p190) BCR-e1 5’-GAC TGC AGC TCC AAT GAG AAC-3’ 
ABL-a2 5’-GTT TGG GCT TCA CAC CAT TCC-3’ 521
4. MLL-AF4 MLL 5’-CCG CCT CAG CCA CCT AC-3’ 
AF4 5’-TGT CAC TGA GCT GAA GGT CG-3’ 559Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 2. Clinical presentation and Hematological data in MPAL cases
Statistical Analysis. The X
2 and the Fischer exact test 
were  used  to  correlate  the  clinical  and  laboratory 
features in the two groups and a p value of ≤0.05 was 
taken as significant. 
Results.  The  total  frequency  of  MPAL  was  6% 
(10/170)  of  all  acute  leukemia  cases  that  underwent 
routine diagnostic evaluation during the study period. 
Out of the 10 MPAL cases, 7/10 (70%) were adult and 
3/10 (30%) were Pediatric cases. The age in adult cases 
ranged from 26-60 years (Mean age 31.5 yrs) and M: F 
ratio was 1.3:1. The age in Pediatric cases ranged from 
7 months – 7 years (Mean age 3.7 years) and all were 
Male children.  The clinical and Hematological data of 
the MPAL cases is outlined in table 2. 
On  Immunophenotyping,  60%  (6/10)  were 
B/Myeloid  and  40%  (4/10)  were T/Myeloid.  The 
incidence of BCR-ABL positivity in MPAL cases was 
40% (4/10). All four MPAL cases positive for BCR-
ABL  transcript  presented  with  High  TLC  and  Low 
platelet count (p value ≤0.05).  3/4 (75%) BCR-ABL 
positive MPAL’s had B/Myeloid phenotype while 1/4 
(25%)  had  T/Myeloid  phenotype.  Molecular  break-
point  was  p210  (b3a2  type)  in  3/4  (75%)  cases  and 
p190  in  1/4  (25%)  case.  The  Immunophenotyping, 
molecular  and  remission  data  in  MPAL  cases  is 
detailed in table 3.  Cytogenetics revealed satisfactory 
metaphases  in  6/10  cases.  Philadelphia  positive 
metaphases were noted in all four BCR-ABL positive 
MPAL  cases  with  a  100%  correlation.  However,  no 
additional cytogenetic abnormality could be identified 
in any of the cases.
Figure 1  and 2 show  RT-PCR  agarose  gels  for 
Housekeeping gene (β-actin) and BCR-ABL transcript 
positive  MPAL  cases.  None  of  the  MPAL  cases 
showed positivity for MLL-AF4 transcript.
Discussion. In the present study all the MPAL cases 
positive for BCR-ABL transcript had high WBC count 
and  low  platelet  count  (p<0.05).  Many  studies  have 
also  shown  BCR-ABL  positive  MPAL’s  presenting 
with high WBC count
4,5, but present study also shows 
relation  of  BCR-ABL  positivity  with  low  platelet 
count.  There  were  4  cases  of  T/Myeloid  MPAL,of
which  one  showed  BCR-ABL  positivity  (Figure 3). 
Mastutes et al
6 in their study had also found BCR-ABL 
positivity  in  13%  (2/15)  cases  with  T/Myeloid 
phenotype.
The  incidence  of  MPAL  cases  was  6%  and  the 
BCR-ABL positivity in present study was 40% which 
is  quiet  comparable  to  few  other  studies  from  the 
subcontinent  and  west.    Studies  from  Asian  sub-
continent by Xu et al
7, Lee et al
8 and Mi et al
9 found 
incidence of MPAL as 4.6%, 2.1% and 3.4% and BCR-
ABL  positivity  as  25.0%,  36.8%  and  16.7% 
respectively.  Studies  from  west  by  Owaidah  et  al
10, 
Carbonell et al
11, Legrand et  al
12, Killick et  al
13 and 
Weir et  al
14 found the incidence of MPAL as 3.4%, 
4.0%, 8.0%, 3.6% and 1.3% and BCR-ABL positivity 
as 9.1%, 30.8%, 35.0%, 38.1% and 18.8% respectively. 
Check marrow is performed at Day 14 in Pediatric 
Acute leukemia cases and Day 28 in adult cases. The 
Complete Hematological Remission rate (CHR) at first 
check marrow after induction therapy was 50% (5/10) 
S.NO. AGE 
(YRS) SEX Lymph Node 
Enlargement Hepatomegaly spleenomegaly
WBC 
COUNT (x 
10
9/L)
PLATELET 
COUNT
(x 10
9/L)
CASE 1 3.5 M +
* (Inguinal) + (Mild) + (Mild) 19.2 45
CASE 2 42 F - + (Mild) + (Mild) 202.4 30
CASE 3 26 F ++
**(cervical) - - 3.1 243
CASE 4 7 M - - - 33.4 31
CASE 5 31 M - +(Mild) + (Mild) 51 25
CASE 6 15 M + (Cervical) - - 72 11
CASE 7 27 F
+++(cervical, 
axillary and 
Inguinal)
- - 6.5 252
CASE 8 28 M - - - 5.1 381
CASE 9 60 F - +(Mild) + (Moderate) 246.6 53
CASE 10 7/12 M - - - 97.4 118Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 3. Immunophenotype and Molecular data and Hematological remission status in MPAL cases.
Figure 1. Beta Actin band positivity as marker of internal cDNA 
quality in all 4 positive MPAL cases (Two per case)
in MPAL cases; 30% cases had no follow
while 20% were not in CHR. Of the four BCR
S.NO.
IMMUNOPHENOTYPIC PROFILE
(B/MYELOID)
CASE 1 CD 19 bright,10,20 & CD 13, 33, 
117, Anti-MPO
CASE 2
CASE 3
CASE 4
CASE 5 CD 19 bright, 10 (>97% ) and 
Anti-MPO (>70% Blasts)
CASE 6
CD 19 bright, CD 10 and CD 13, 
33, Anti-MPO, 11b, 11c, 4dim, 
34, 123, 45
CASE 7
CASE 8
CD 19, 22, 79a, 34, DR, 123, 38, 
Tdt and CD 13, 33, 117, Anti
MPO
CASE 9 CD 19, 34, DR, 123, 38, Tdt, and 
CD 13, 33, 117, Anti-MPO
CASE 10
CD 19, 22, 79a (>40%) and CD 4, 
14, 16, 33, DR, Anti-MPO (> 
60% Blasts)- B/Monocytoid
Infantile Leukemia
TOTAL 10 6/10 (60%) 
: Open Journal System
ar data and Hematological remission status in MPAL cases.
Beta Actin band positivity as marker of internal cDNA 
quality in all 4 positive MPAL cases (Two per case)
in MPAL cases; 30% cases had no follow-up details 
while 20% were not in CHR. Of the four BCR-ABL 
Figure 2. Agarose  gel showing  BCR
MPAL cases. Lane 1: Case 1 (Positive; b3a2 transcript
Lane 2: Case 6 (Positive; e1a2 transcript
pattern 100bp. Lane 5: Case 2 (Positive; b3a2 transcript
Lane 8: Case 10 (Positive; b3a2 transcript
positive cases 75% (3/4) were in CHR and all these 
IMMUNOPHENOTYPIC PROFILE MOLECULAR 
PROFILE
(T/MYELOID) BCR-ABL (9;22)
CD 19 bright,10,20 & CD 13, 33,  POSITIVE-p210 
(b3a2) Transcript
CD 2, 3, 4, 7, cCD3, CD 56 
(>90%) and CD 13, 117, Anti-
MPO (> 30%)
POSITIVE-p210 
(b3a2) Transcript
cCD3, 2, 5, 7, 4, 8, TdT and 
CD13, 33, Anti-MPO         -
cCD3, 2, 5, 7, TdT, 4, 8, TCR dim 
and CD13, 33, Anti-MPO -                              
CD 19 bright, 10 (>97% ) and          -
CD 19 bright, CD 10 and CD 13, 
MPO, 11b, 11c, 4dim, 
  POSITIVE-
p190 (e1a2) 
Transcript
cCD3, 2, 5, 7, 4, 8, TdT and 
CD13, Anti-MPO -               
CD 19, 22, 79a, 34, DR, 123, 38, 
and CD 13, 33, 117, Anti-       -
CD 19, 34, DR, 123, 38, Tdt, and    POSITIVE-
p210 (b3a2) 
Transcript
CD 19, 22, 79a (>40%) and CD 4, 
MPO (> 
Monocytoid-   -
4/10 (40%)  4/10 (40%) 
Agarose  gel showing  BCR-ABL positivity in the four 
Lane 1: Case 1 (Positive; b3a2 transcript- 385bp). 
transcript- 521bp). Lane 4: Ladder 
Lane 5: Case 2 (Positive; b3a2 transcript- 385bp). 
Lane 8: Case 10 (Positive; b3a2 transcript- 385bp).
positive cases 75% (3/4) were in CHR and all these 
MOLECULAR 
PROFILE
Post Induction check 
marrow (Hematological 
Remission Status)
ABL (9;22)
p210 
(b3a2) Transcript In Remission
p210 
(b3a2) Transcript In Remission 
Not  in Remission (9% 
blasts)
                              No follow-up
In Remission
Not  in Remission (60% 
blasts)
               No follow-up
No follow-up
In Remission
In RemissionMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure 3. Geimsa Stain- PBF (1000X); Two population of Blasts. 
Arrow- Blast showing presence of Auer Rod like granules
were positive for b3a2 transcript type (p<0.05%). Only 
one  BCR-ABL  positive  MPAL  (p190  transcript) 
showed  60%  blasts  in  Bone  marrow  at  1
st check 
marrow. However, the case number and positivity for 
p190 transcript is low and the follow-up data is limited 
to  derive  any  conclusive  statement  regarding 
prognostic difference between the two transcript types 
in  MPAL  cases.  The  MPAL  cases  are  treated  with 
ALL/AML  standard  induction  protocol  based  on 
predominant  Blast  immunophenotype.  In  addition 
Imatinib  is  added  to  the  treatment  regimen  if  the 
MPAL case is BCR-ABL positive on RT-PCR. All the 
above four BCR-ABL positive MPAL cases received 
Imatinib along with standard induction regimen drugs. 
The good response in three cases could be attributed to 
the possible favorable effect of Imatinib addition to the 
standard  induction  regimen,  which  is  quiet  well 
described in literature . However long term follow up 
data  in  more  number  of  cases  is  needed  to  further 
substantiate the findings. None of our MPAL case was 
positive for MLL-AF4 transcript. However we had not 
looked for other MLL rearrangements in these cases.
Conclusions.  Immunophenotyping  of  all  acute 
leukemia cases is necessary with a complete panel of 
lineage specific markers to detect presence of Mixed 
Phenotype Acute leukemias. RT-PCR for BCR-ABL is 
also  mandatory  in  all  MPAL  cases  as  the  overall 
prognosis in these patients may improve with addition
of Imatinib (Gleevac /STI571) therapy to the  treatment 
regimen. 
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